Argenx Q3 Vyvgart Sales Jump 54 Percent
Belgian pharmaceutical firm argenx reported that third-quarter sales of its autoimmune drug Vyvgart rose 54 percent to 1.7 billion dollars. Operating profit missed estimates due to acquisition costs from its recent purchase of Forte Biosciences.
Xurve View
Insights:
Xurve View
ARGENX SE - ADR reported global sales of its flagship autoimmune drug surged 54% to $1.7B in the third quarter, driven by expanded patient reach. The Belgium and Netherlands-headquartered drugmaker continues to scale its commercial footprint despite rising overhead. Investors are weighing the strong top-line momentum against operating margins that missed consensus estimates due to recent dealmaking.
